Exploring the Clinical Benefit of Docetaxel or Enzalutamide after Disease Progression during Abiraterone Acetate and Prednisone Treatment in Men with Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer

Volumn 13, Issue 4, 2015, Pages 392-399

  Zhang, Tian ^a   Dhawan, Mallika S ^b   Healy, Patrick ^a   George, Daniel J ^a   Harrison, Michael R ^a   Oldan, Jorge ^a   Chin, Bennett ^a   Armstrong, Andrew J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abiraterone; Castration resistant prostate cancer; Cross resistance; Docetaxel; Enzalutamide

Indexed keywords

ABIRATERONE ACETATE; ALBUMIN; ALKALINE PHOSPHATASE; CABAZITAXEL; CARBOPLATIN; DOCETAXEL; ENZALUTAMIDE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PAZOPANIB; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TASQUINIMOD; ABIRATERONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PHENYLTHIOHYDANTOIN; TAXOID;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG RESPONSE; FOLLOW UP; GLEASON SCORE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MEDICAL RECORD REVIEW; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; BLOOD; DISEASE FREE SURVIVAL; DRUG RESISTANCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY;

ABIRATERONE ACETATE; AGED; AGED, 80 AND OVER; ANDROSTENES; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84936986429     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2015.01.004     Document Type: Article

References (31)

1. C.J. Ryan, M.R. Smith, and J.S. de Bono Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
2. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
3. T.M. Beer, A.J. Armstrong, and D.E. Rathkopf Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424 433
4. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
5. S. Badrising, V. van der Noort, and I.M. van Oort Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment Cancer 120 2014 968 975
6. D. Bianchini, D. Lorente, and A. Rodriguez-Vida Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone Eur J Cancer 50 2014 78 84
7. Y. Loriot, D. Bianchini, and E. Ileana Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 2013 1807 1812
8. S.C. Schmid, A. Geith, and A. Boker Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer Adv Ther 31 2014 234 241
9. A.J. Schrader, M. Boegemann, and C.H. Ohlmann Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone Eur Urol 65 2014 30 36
10. F.B. Thomsen, M.A. Roder, P. Rathenborg, K. Brasso, M. Borre, and P. Iversen Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate Scand J Urol 48 2014 268 275
11. A.A. Azad, B.J. Eigl, R.N. Murray, C. Kollmannsberger, and K.N. Chi Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients Eur Urol 67 2015 23 29
12. Brasso K, Thomsen FB, Schrader AJ, et al. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis. Eur Urol, Published online August 6, 2014; http://dx.doi.org/10.1016/j.eururo.2014.07.028.
13. D.L. Suzman, B. Luber, M.T. Schweizer, R. Nadal, and E.S. Antonarakis Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone Prostate 74 2014 1278 1285
14. M.T. Schweizer, X.C. Zhou, and H. Wang The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer Eur Urol 66 2014 646 652
15. E.S. Antonarakis, C. Lu, and H. Wang AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer N Engl J Med 371 2014 1028 1038
16. M. Thadani-Mulero, L. Portella, and S. Sun Androgen receptor splice variants determine taxane sensitivity in prostate cancer Cancer Res 74 2014 2270 2282
17. K.E. Ware, M.A. Garcia-Blanco, A.J. Armstrong, and S.M. Dehm Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer Endocr Relat Cancer 21 2014 T87 103
18. V.K. Arora, E. Schenkein, and R. Murali Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade Cell 155 2013 1309 1322
19. J.D. Joseph, N. Lu, and J. Qian A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509 Cancer Discov 3 2013 1020 1029
20. M. Korpal, J.M. Korn, and X. Gao An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) Cancer Discov 3 2013 1030 1043
21. H. Beltran, D.S. Rickman, and K. Park Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets Cancer Discov 1 2011 487 495
22. R. Aggarwal, T. Zhang, E.J. Small, and A.J. Armstrong Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes J Natl Compr Canc Netw 12 2014 719 726
23. B.S. Taylor, N. Schultz, and H. Hieronymus Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
24. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
25. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
26. M.D. Balbas, M.J. Evans, and D.J. Hosfield Overcoming mutation-based resistance to antiandrogens with rational drug design Elife 2 2013 e00499
27. S. Carreira, A. Romanel, and J. Goodall Tumor clone dynamics in lethal prostate cancer Sci Transl Med 6 2014 254ra125
28. Y. Li, S.C. Chan, L.J. Brand, T.H. Hwang, K.A. Silverstein, and S.M. Dehm Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines Cancer Res 73 2013 483 489
29. Al Nakouzi N, Le Moulec S, Albiges L, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol, Published online May 2, 2014; http://dx.doi.org/10.1016/j.eururo.2014.04.015.
30. C.J. Pezaro, A.G. Omlin, and A. Altavilla Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents Eur Urol 66 2014 459 465
31. van Soest RJ, de Morree ES, Kweldam CF, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur Urol, Published online December 4, 2014; http://dx.doi.org/10.1016/j.eururo.2014.11.033.